treatment, marrow blasts increased to 40%. FISH for BCR-ABL remained negative (also negative with the sorted CD34 þ / CD38 þ and CD34 þ /CD38-population) whereas À7 was present in 82% of the marrow cells. Quantitative PCR analysis was not performed. However, with nested RT-PCR using sets of BIOMED primers 2 the e1a2 transcript was still detectable suggesting presence of a very small and quiescent population of imatinib-resistant BCR-ABL-positive leukemic stem cells.
Molecular biology is a powerful tool for investigating acute myeloid leukemia (AML). Given that concerted efforts have documented the reliability and clinical utility of the real-time quantitative polymerase chain reaction (RQ-PCR) for detecting fusion transcripts in AML, 1 it is not surprising that similar assays have been sought for in the sizeable fraction of AML cases without balanced translocations. The Wilms' tumor gene 1 (WT1) has received close attention in this respect. Initially described in childhood genitourinary cancers, the gene has subsequently been shown to be overexpressed in a number of different cancers. Although its exact function in the evolvement of a malignant clone is still a matter of debate, its role as an minimal residual disease (MRD) target in myelodysplastic syndrome and AML is now amply documented. 2, 3 Indeed, recent data from our laboratory suggest that the assay is able to predict relapse months ahead of morphological relapse. 2, 4 In de novo AML relapses are often thought to emerge from exactly the same clone as at diagnosis. This is in contrast to the situation in, for example, pre-B acute lymphoid leukemia, where IgH gene rearrangements have disclosed clonal instability.
In this report, we present evidence that clonal heterogeneity with regard to WT1 may be present at diagnosis and that chemotherapy-resistant subclones can be selected for during chemotherapy.
A Figure 1 (a) WT1 expression in PB over time from diagnosis to second relapse. Y axis: log reduction from diagnostic sample. The clinical state at a given time point is indicated on the top of the graph. The blue solid line represents our standard primer/probe set, whereas the red solid line corresponds to our alternative set. The dashed lines symbolize the sensitivities of the RQ-PCR at the given day of sampling calculated as described previously. 2 The normal background level of WT1 is illustrated with a green dashed line. The mutational status of WT1 in respectively genomic DNA and cDNA is indicated on the bottom of the graph. These results are generated from the fragment analysis in which fractions of the 8 bp deletion in WT1 are calculated. NA: samples are not analyzed owing to lack of material, no WT1: no PCR product was amplified owing to the low level of the fusion transcript in the remission samples. (b) Fragment analysis of genomic DNA showing the shift from wild-type (wt) DNA at diagnosis to the 8 bp deletion (del) at second relapse. Red spikes represent a molecular weight marker. (c) Silver-stained gel and Western blot. Lane1: diagnostic sample, 2: sample at second relapse, 3: negative control (a sample from an AML patient in remission) and 4: positive control (cell line K562) (lanes not relevant for this study have been omitted).
Letters to the Editor specific WT1 primer and probe sequences: Forward primer (exon 6): 5 0 -AGAATACACACGCACGGTGTCT-3 0 , reverse primer (exon 7): 5 0 -GATGCCGACCGTACAAGAGTC-3 0 , probe (exon 6/7): FAM-5 0 -CTCCAGGCACACGTCGCACATCCTG-3 0 -TAMRA. 2 An alternative primer/probe set was designed using human LNA (locked nucleic acid) probe no. 4 (exon 7) 5 0 -GCAGGAAG-3 0 (Exiqon, Vedbaek, Denmark) in combination with a forward primer (exon 7
Quantification of the amount of mutated cDNA and DNA was done using the formula: Sm/(Sw þ Sm), where Sm is the spike intensity representing the PCR product harboring the mutation and Sw is the spike intensity representing the wild-type PCR product.
20 ml of MNC stored in messenger RNA (mRNA) lysis buffer (Roche Diagnostics, Basel, CH) was loaded directly on a sodium dodecylsulfate polyacrylamide gel. Protein was detected by Western blot using a monoclonal antibody (ab3236, Abcam, Cambridge, UK) corresponding to amino acids 1-318 of WT1 and an alkaline phosphate-conjugated secondary antibody (DAKO A/S, Copenhagen, DK). A silver-stained gel was performed by loading 2 ml of MNC in mRNA lysis buffer (Roche Diagnostics) in each slot.
The patient was sampled for PB and BM at multiple time points during the course of disease. As demonstrated earlier, 2 RQ-PCR data from PB and BM were similar. The WT1 gene expression measured by our standard primer/probe set 2 in PB mirrored the clinical course up to and including the first relapse, comprising an increase of expression heralding the clinical relapse (Figure 1a) . Surprisingly, the expression of WT1 was lost up to and at the second relapse in clear contradiction to immunophenotype and morphology. This prompted us to construct a differently located primer/probe set, and employing this, the WT1 expression was found to be consistent with clinical data displaying gradual increases up to the time of second relapse (Figure 1a) .
We hypothesized that the reason for this discrepancy could be a mutation in WT1 located within the annealing sites of our standard primer/probe set, which spans exon 6 and 7 in contrast to our alternative set, which cover exon 7 and 8 ( Figure 2a) . Indeed, an 8 bp deletion was demonstrated by PCR and sequencing (Figure 2b and c) . To study whether the deletion was present at diagnosis we performed fragment analysis of the deleted region using both genomic DNA and cDNA as targets. Interestingly, we found minor spikes (3-5%) representing the deletion already at the time of diagnosis (Figure 1b) . Not shown in the Figure, which only depicts measurement of PB is that at first relapse (March 2004) BM revealed 5% of the truncated clone. By computer analysis the 8 bp deletion resulted in a truncated protein terminating before the zinc-finger domain. Corroborating the molecular data, Western blot demonstrated WT1 expressed at diagnosis but not at second relapse (Figure 1c) .
Mutations within WT1 in cancer have been known for some time, varying from disease to disease. They are rare in AML though there have been reports of alterations in exon 7 leading to a truncated protein terminating before the zinc-finger region. 6, 7 Importantly, none of these mutations have to our knowledge been investigated more than once throughout the disease course. A single patient harboring a point mutation in exon 9 was investigated both at diagnosis and at relapse showing the mutation to occur only at relapse. 7 Although the observation in this patient might cast doubt on WT1 as an MRD target, we would like to stress that this falsenegative result is a rare event, as WT1 expression remained high at subsequent relapses in 24 other AML patients we have tested longitudinally.
The present case story demonstrates for the first time in AML that a minor subclone, characterized by a mutation in WT1 and present already at diagnosis, develops to be the dominant clone after repeated courses of chemotherapy including SCT. A plausible explanation for these observations may be that the mutant clone is less sensitive to the therapy given in second treatment course than the primary clone. The mechanism for this resistance development and its possible direct or indirect relation to WT1 is not clear. Indeed, the contribution of WT1 overexpression in malignant blood diseases is not resolved, even though a very recent report has shown that the gene can be pivotal in leukemogenesis in WT1 transgenic mice, in which AML/ETO-transduced BM cells developed rapidly into AML in contrast to the situation in non-transgenic animals, which only developed anemia and dysplasia. 8 Even though it cannot be formally excluded, we feel that the t(6;12) aberration could only contribute marginally to the course of disease, as it first appeared at the final relapse. Nevertheless, our data are supported by previous reports which have speculated that mutations in WT1 could lead to progression of the leukemia by conferring drug resistance. 6, 7 These findings have wide-ranging implications for our knowledge of the biology of AML and for its clinical follow-up. The primary granule protein (PGP), human neutrophil elastase (HNE), is often associated with inflammatory-type reactions but also has a role in granulopoiesis.
1 PGP proteases, including HNE, normally provide negative feedback of granulopoiesis by controlling the availability of granulocyte colony-stimulating factor (G-CSF) proportionate to the relative abundance of mature granulocytes that are greatly elevated in number as a clinical feature of chronic myeloid leukaemia (CML).
HNE added to normal CD34 þ stem cells in culture blocks granulocyte macrophage (GM) colony formation and induces apoptosis.
1,2 The G-CSF receptor is not digested; instead HNE targets G-CSF protein exerting a negative feedback on cytokine activity. 1 High plasma levels of HNE 2 and low G-CSF 3 have been reported in CML. Moreover, it is known that Ph þ cells can invoke autocrine G-CSF cytokine production. 4 Taken together, these data suggest that HNE may contribute to the CML phenotype of Ph þ clonal dominance as Ph À normal cells die without growth factors.
Indeed, it has been shown that CML CD34 þ cells are insensitive to exogenously added HNE, whereas normal CD34 þ that are not cytokine-independent undergo apoptosis when cultured in vitro in serum-free medium supplemented with stem cell factor, G-and GM-CSF to which HNE is added. 2 Elafin is a naturally occurring inhibitor of HNE, and can restore normal proliferation when added to mixed CML/normal cell cultures (El-Ouriaghli et al. Blood 2003; 102: 230a; abstract). We sought to determine whether HNE levels are elevated in CML bone marrow (BM) and peripheral blood (PB) samples taken pre-and post-treatment with the tyrosine kinase inhibitor, imatinib mesylate (IM) and to determine any correlation with disease stage. Consequently, it may be possible to target HNE with an inhibitor modelled on the naturally occurring anti-protease, elafin or elastase-specific inhibitor. 5 PB or BM samples were collected into ethylenediaminetetraacetic acid tubes from CML and non-CML patients; PB was also drawn from healthy volunteers, all with informed consent. Non-CML and healthy individuals had white blood cell counts (WBC) in the normal range (o10 Â 10 9 /l). Samples from CML patients were collected at various time intervals before and during the course of their treatment with IM. The plasma supernatant from all samples was separated from cellular components by centrifugation and stored frozen (À201C) until required. A total of 105 samples were analysed (Table 1) . HNE protein was measured using a highly sensitive, specific enzyme-linked immunosorbent assay (ELISA) kit (BioVendor, The Netherlands) for the quantitative measurement of the complex of HNE with alpha-1 proteinase inhibitor in plasma. Serum was not suitable as during clotting, HNE can be released in vitro.
Measurement of plasma HNE by ELISA showed that at diagnosis (chronic phase (CP) CML, n ¼ 16), PB HNE was significantly elevated (1934795 ng/ml, mean7s.e.m.) with respect to normal controls (6473 ng/ml, n ¼ 9; P ¼ 0.002) 
